Technology Summary
A-CUBE uses proprietary algorithms to identify novel druggable sites on protein targets. Potential therapeutics targeting these sites represent new potential sources of significant revenue to address slowed growth in the pharmaceutical industry.Developed by A-CUBE's founder, Dr. Nobu Ota, the predictive algorithms exploit 3-dimensional (3D) protein structures, identifying specific, novel druggable sites. These algorithms have application in small and large molecule discovery as well as vaccine programs.